Home › Compare › FSXLF vs ABBV
FSXLF yields 596.57% · ABBV yields 3.06%● Live data
📍 FSXLF pulled ahead of the other in Year 1
Combined, FSXLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FSXLF + ABBV for your $10,000?
Great Pacific Gold Corp., a junior exploration company, engages in the acquisition, exploration, and development of mineral properties in Australia and Papua New Guinea. It primarily explores for copper and gold deposits. The company's flagship projects include the Wild Dog project comprising two granted exploration licenses covering an area of 1422 square kilometers located in the island of New Britain, Papua New Guinea; and the Kesar Creek project which comprises one granted exploration license covering an area of 130 square kilometers, as well as the Arau project which consists of two granted exploration licenses covering approximately 614 square kilometers both located in the Kainantu region, Eastern Highlands Province, Papua New Guinea. The company was formerly known as Fosterville South Exploration Ltd. and changed its name to Great Pacific Gold Corp. in September 2023. Great Pacific Gold Corp. was incorporated in 2019 and is headquartered in Vancouver, Canada.
Full FSXLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.